Responses
Regular and Young Investigator Award Abstracts
Clinical Trials Completed
596 Results from a phase 1 study of CDX-1140, a fully human anti-CD40 agonist monoclonal antibody (mAb), in combination with pembrolizumab
Compose a Response to This Article
Other responses
No responses have been published for this article.